


An unusual myelofibrosis

Véronique Vergé and Peggy Dartigues, Gustave Roussy



A 68-year-old patient was admitted for increased splenomegaly after 6 months of treatment with ruxolitinib for primary myelofibrosis (PMF). No JAK2 V617F/exon12- MPL- CAL-R or other mutations were detected in next-generation sequencing analysis (77 genes panel). Bone marrow biopsy showed increased cellularity (panel A, original magnification $\times 100$) with grade 2 myelofibrosis based on reticulin stain (panel B, original magnification $\times 200$). There was no improvement after addition of hydroxyurea. The blood cell count on admission showed mild neutropenia and thrombocytopenia, a discrete hyperlymphocytosis ($4\text{--}5 \times 10^9/\text{L}$) with presence of abnormal lymphocytes on the blood film, some with cytoplasmic granules, others with a blastic appearance with nucleoli (panel D, original magnification $\times 1000$). The flow

cytometry analysis showed 85% natural killer (NK) cells, CD7⁺/sCD3⁻/CD2⁺/CD5⁻/CD4⁻/CD8⁻/CD56⁺/CD16⁺ low/CD57⁻. The diagnosis of aggressive NK cell leukemia was made. Histological review of the initial bone marrow biopsy showed interstitial and sinusoidal infiltration by NK cells (panel C, CD7 stain, original magnification $\times 200$). Karyotyping of peripheral blood cells showed a hypodiploid complex karyotype. The disease progressed rapidly despite 2 lines of treatment.

This case reminds us that myelofibrosis is not only seen in myeloproliferative neoplasms. Careful histological analysis should be performed in triple-negative PMF to not miss clues for other diagnoses.